High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
211.42K
-9.65%
-0.365
-40.23%
147.00K
-57.02%
-0.382
+52.67%
125.00K
-56.9%
-0.363
+25.29%
Estimates Revision
The market is revising Downward the revenue expectations for Perspective Therapeutics, Inc. (CATX) for FY2025, with the revenue forecasts being adjusted by -5.12% over the past three months. During the same period, the stock price has changed by -30.92%.
Revenue Estimates for FY2025
Revise Downward
-5.12%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+5.26%
In Past 3 Month
Stock Price
Go Down
-30.92%
In Past 3 Month
10 Analyst Rating
Wall Street analysts forecast CATX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CATX is 11.40 USD with a low forecast of 5.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 2.390
Low
5.00
Averages
11.40
High
18.00
Current: 2.390
Low
5.00
Averages
11.40
High
18.00
Truist
NULL -> Buy
initiated
$8 -> $12
2025-11-24
Reason
Truist
Price Target
$8 -> $12
2025-11-24
initiated
NULL -> Buy
Reason
Truist assumed coverage of Perspective Therapeutics with a Buy rating with a price target of $12, up from $8. The company is leading the next wave of radiopharmaceutical innovation, combining manufacturing readiness with cutting-edge molecular design to deliver precision oncology at scale, the analyst tells investors in a research note. Perspective's lead program VMT-alpha-NET has a promising interim phase 1/2B profile, and additional programs in melanoma and FAP offer upside, the firm added.
UBS
David Lai
Buy
downgrade
$18 -> $7
2025-11-21
Reason
UBS
David Lai
Price Target
$18 -> $7
2025-11-21
downgrade
Buy
Reason
UBS analyst David Lai lowered the firm's price target on Perspective Therapeutics to $7 from $18 and keeps a Buy rating on the shares.
UBS
David Lai
Buy
downgrade
$18 -> $7
2025-11-20
Reason
UBS
David Lai
Price Target
$18 -> $7
2025-11-20
downgrade
Buy
Reason
UBS analyst David Lai lowered the firm's price target on Perspective Therapeutics to $7 from $18 and keeps a Buy rating on the shares. The Q3 press release highlighted upcoming data updates in 1H26 for lead program VMT-alpha-NET, with the firm saying we should expect an additional 23 patients as early as Q1 as well as durability from existing patients. The firm added that it believes increased competition may impact commercial adoption of VMT-alpha-NET.
Oppenheimer
Oppenheimer
Outperform
maintain
$14 -> $13
2025-11-11
Reason
Oppenheimer
Oppenheimer
Price Target
$14 -> $13
2025-11-11
maintain
Outperform
Reason
Oppenheimer lowered the firm's price target on Perspective Therapeutics (CATX) to $13 from $14 and keeps an Outperform rating on the shares following the company's Q3 business update on Monday afternoon. The update follows recent positive results for VMT-alpha-NET presented at ESMO, with Perspective down 29% on the day, after competitor Sanofi (SNY)/Oranomed presented updated Alphamedix02 results with a 60% ORR in the same session. In Oppenheimer's view key differences between the studies make this a more competitive story than the headline numbers suggest, keeping the firm cautiously optimistic.
Oppenheimer
Oppenheimer
Outperform
maintain
$14
2025-09-15
Reason
Oppenheimer
Oppenheimer
Price Target
$14
2025-09-15
maintain
Outperform
Reason
Oppenheimer reiterated an Outperform rating and $14 price target on Perspective Therapeutics after the firm hosted the company's leadership team for an investor dinner last week. The firm said it came away with increased confidence that the VMT-alpha-NET update at ESMO on October 20 will build on prior results presented this summer at ASCO, while cautioning on setting a bar for response rates given the uncertainty on the length of follow-up for these patients. The 6mCi dose seeks to improve efficacy while preserving the safety margin or VMT-alpha-NET, and management seems confident in 5mCi as a potential go-forward dose in a registrational trial, the analyst tells investors in a research note.
B. Riley
Buy
maintain
$9 -> $12
2025-06-23
Reason
B. Riley
Price Target
$9 -> $12
2025-06-23
maintain
Buy
Reason
B. Riley raised the firm's price target on Perspective Therapeutics to $12 from $9 and keeps a Buy rating on the shares. The firm says sequential positive updates from Perspective drive the higher price target. It now sees an increased probabiliry of success for VMT-alpha-NET to deliver best-in-class efficacy and safety profile.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Perspective Therapeutics Inc (CATX.A) is -1.60, compared to its 5-year average forward P/E of -12.76. For a more detailed relative valuation and DCF analysis to assess Perspective Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-12.76
Current PE
-1.60
Overvalued PE
5.46
Undervalued PE
-30.97
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-5.18
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
7.58
Undervalued EV/EBITDA
-17.93
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
224.62
Current PS
0.00
Overvalued PS
729.67
Undervalued PS
-280.42
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
CATX News & Events
Events Timeline
(ET)
2025-11-10
16:26:16
Perspective Therapeutics announces Q3 earnings per share of 35 cents, surpassing consensus estimate of 32 cents.
2025-10-20 (ET)
2025-10-20
14:08:16
Perspective Therapeutics Declines Following Phase 1/2a Trial Update
2025-10-02 (ET)
2025-10-02
07:05:36
Perspective Therapeutics reports treatment of first patient with PSV359
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/775c60ffc0377d98d066eb98a8eeafd7e4d45726150911da0943e50e24e548b9.png)
Preview
4.0
11-25BenzingaTruist Securities Initiates Coverage on Perspective Therapeutics with a Buy Rating and Increases Price Target to $12
Preview
6.0
11-22BenzingaUBS Reiterates Buy Rating for Perspective Therapeutics, Adjusts Price Target to $7
Preview
1.0
11-20NewsfilterPerspective Therapeutics to Attend Conferences Scheduled for December
Sign Up For More News
People Also Watch
FAQ
What is Perspective Therapeutics Inc (CATX) stock price today?
What is Perspective Therapeutics Inc (CATX)'s business?
What is the price predicton of CATX Stock?
What is Perspective Therapeutics Inc (CATX)'s revenue for the last quarter?
What is Perspective Therapeutics Inc (CATX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Perspective Therapeutics Inc (CATX)'s fundamentals?
How many employees does Perspective Therapeutics Inc (CATX). have?